-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Stock (TNXP) Hits A New All-Time Low: What's Going On?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares traded lower by 7.2% to $0.17 Monday morning, hitting a new-all time low. The stock is trading lower on downward momentum after the company last week announced the pricing of a $4.4 million registered direct offering.
Tonix has initiated a securities purchase agreement with existing healthcare-focused institutional investors for the sale of 14,666,666 shares of its common stock and accompanying warrants in a registered direct offering at a combined price of $0.30 per share.
The offering, expected to close around April 1, is anticipated to generate gross proceeds of approximately $4.4 million. The net proceeds will be allocated towards working capital, general corporate purposes, and partial repayment of debt. A.G.P./Alliance Global Partners is the sole placement agent for the offering.
In addition to the offering, the company has agreed to amend certain existing warrants issued in 2023, reducing their exercise price to $0.33 per share and extending their termination dates.
These amendments are contingent upon shareholder approval, and if not obtained within six months of the offering's closing, the warrants will have an exercise price equal to the Nasdaq minimum price.
China's March Manufacturing Growth Could 'Dump Into Global Markets, Thus Triggering Deflation,' Expert Warns
Should I Sell My TNXP Stock?
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Tonix Pharmaceuticals have decreased by 94.6% in the past year. An investor who bought shares of Tonix Pharmaceuticals at the beginning of the year would take a loss of $0.22 per share if they sold it today. The stock has fallen 48.56% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital loss of $0.18.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Tonix Pharmaceuticals stock currently has an RSI of 12.61, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
TNXP has a 52-week high of $3.80 and a 52-week low of $0.17.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares traded lower by 7.2% to $0.17 Monday morning, hitting a new-all time low. The stock is trading lower on downward momentum after the company last week announced the pricing of a $4.4 million registered direct offering.
周一上午,Tonix制药控股公司(纳斯达克股票代码:TNXP)股价下跌7.2%,至0.17美元,创历史新低。该公司上周宣布了440万美元注册直接发行的定价后,该股在下跌势头下跌。
Tonix has initiated a securities purchase agreement with existing healthcare-focused institutional investors for the sale of 14,666,666 shares of its common stock and accompanying warrants in a registered direct offering at a combined price of $0.30 per share.
Tonix已与现有以医疗保健为重点的机构投资者启动了证券购买协议,以注册直接发行的形式出售14,666,666股普通股和附带的认股权证,总价格为每股0.30美元。
The offering, expected to close around April 1, is anticipated to generate gross proceeds of approximately $4.4 million. The net proceeds will be allocated towards working capital, general corporate purposes, and partial repayment of debt. A.G.P./Alliance Global Partners is the sole placement agent for the offering.
此次发行预计将于4月1日左右结束,预计将产生约440万美元的总收益。净收益将用于营运资金、一般公司用途和部分债务偿还。A.G.P./Alliance Global Partners是本次发行的唯一配售代理人。
In addition to the offering, the company has agreed to amend certain existing warrants issued in 2023, reducing their exercise price to $0.33 per share and extending their termination dates.
除此次发行外,该公司还同意修改2023年发行的某些现有认股权证,将其行使价降至每股0.33美元,并延长其终止日期。
These amendments are contingent upon shareholder approval, and if not obtained within six months of the offering's closing, the warrants will have an exercise price equal to the Nasdaq minimum price.
这些修正案取决于股东的批准,如果在发行结束后的六个月内没有获得认股权证,则认股权证的行使价将等于纳斯达克的最低价格。
China's March Manufacturing Growth Could 'Dump Into Global Markets, Thus Triggering Deflation,' Expert Warns
专家警告说,中国3月份的制造业增长可能 “倾向全球市场,从而引发通货紧缩”
Should I Sell My TNXP Stock?
我应该卖掉我的TNXP股票吗?
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
在决定持有或出售股票时,投资者应考虑其时间范围、未实现收益和总回报。
Shares of Tonix Pharmaceuticals have decreased by 94.6% in the past year. An investor who bought shares of Tonix Pharmaceuticals at the beginning of the year would take a loss of $0.22 per share if they sold it today. The stock has fallen 48.56% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital loss of $0.18.
在过去的一年中,Tonix Pharmicals的股价下跌了94.6%。年初购买Tonix Pharmicals股票的投资者如果今天出售,则每股亏损0.22美元。该股在过去一个月中下跌了48.56%,这意味着在3月1日购买股票的投资者将遭受0.18美元的资本损失。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Tonix Pharmaceuticals stock currently has an RSI of 12.61, indicating oversold conditions.
投资者也可以考虑市场动态。相对强弱指数可用于表明股票是超买还是超卖。Tonix Pharmicals股票目前的相对强弱指数为12.61,这表明存在超卖情况。
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
要访问高级制图和分析工具以及股票数据,请查看 Benzinga PRO。免费试用。
TNXP has a 52-week high of $3.80 and a 52-week low of $0.17.
腾讯智浦的52周高点为3.80美元,52周低点为0.17美元。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧